Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.
Interventions
DRUGinsulin degludec/liraglutide
Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are related to the recording of data and determining the suitability for the study according to the protocol. Some specific historical data collected before informed consent is obtained can be used as baseline data (HbA1c, FPG/FBG and others) * The decision to initiate treatment with commercially available Xultophy™ has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study * Male or female, age at least 18 years at the time of signing the informed consent * Patients diagnosed with type 2 diabetes mellitus * Patients who are scheduled to start treatment with Xultophy™ based on the clinical judgement of their treating physician
Exclusion criteria
* Known or suspected hypersensitivity to Xultophy™, any of the active substances, any of the excipients or any related products * Previous participation in this study. Participation is defined as signed informed consent * Mental incapacity, unwillingness or language barriers hindering adequate understanding or cooperation * Females who are pregnant, breast-feeding or intend to become pregnant within the following 12 months * Patients who are participating in other studies or clinical trials. * Any disorder which in the opinion of the Physician might jeopardise subject's safety or compliance with the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment emergent Adverse Events (AEs) | Year 0-1 | Count and % of events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Serious Adverse Drug Reactions (SADRs) | Year 0-1 | Count and % of events |
| Number of Adverse Drug Reactions (ADRs) | Year 0-1 | Count and % of events |
| Number of confirmed hypoglycaemic episodes | Year 0-1 | Count of episodes |
| Change from baseline in the level of glycosylated haemoglobin (HbA1c) | Year 0, Year 1 | Measured in % |
| Number of Serious Adverse Events (SAEs) | Year 0-1 | Count and % of events |
| Percentage of patients achieving the target level of HbA1c below 7% | Year 1 | Measured in % |
| Change in body weight | Year 0, Year 1 | Measured in kg and/or % |
| Number of patients withdrawn due to ineffective therapy | Year 1 | Count of withdrawals |
| Change in the level of Fasting Plasma/Blood Glucose (FPG/FBG) from baseline | Year 0, Year 1 | Measured in mg/dl or other equivalent SI units |
Outcome results
None listed